Danaher Co. (NYSE:DHR) Holdings Lifted by Strategic Wealth Investment Group LLC

Strategic Wealth Investment Group LLC grew its holdings in shares of Danaher Co. (NYSE:DHR) by 11.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,176 shares of the conglomerate’s stock after buying an additional 4,263 shares during the period. Strategic Wealth Investment Group LLC’s holdings in Danaher were worth $9,452,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Decker Retirement Planning Inc. acquired a new stake in shares of Danaher in the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher in the third quarter worth approximately $40,000. FSA Wealth Management LLC bought a new position in Danaher during the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter valued at $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DHR has been the subject of several research reports. Robert W. Baird decreased their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Jefferies Financial Group lowered their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday. Stephens reissued an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, Raymond James decreased their price target on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Stock Performance

Shares of DHR opened at $223.16 on Friday. Danaher Co. has a 52 week low of $221.34 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market capitalization of $161.19 billion, a PE ratio of 42.27, a PEG ratio of 4.22 and a beta of 0.83. The company’s 50 day moving average price is $235.89 and its 200 day moving average price is $253.45.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period in the prior year, the firm earned $2.09 EPS. Research analysts expect that Danaher Co. will post 8.15 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.48%. Danaher’s payout ratio is 20.45%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.